Geode Capital Management
ESLA icon

Geode Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Geode Capital Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$65.9K Sell
141,138
-183
-0.1% -$131 ﹤0.01% 4149
2026
Q2 		$147K Sell
141,321
-16,164
-10% -$21.1K ﹤0.01% 4012
2026
Q1 		$167K Buy
157,485
+47,677
+43% +$54.8K ﹤0.01% 3979
2025
Q4 		$171K Buy
109,808
+8,318
+8% +$15.7K ﹤0.01% 3962
2025
Q3 		$121K Sell
101,490
-1,847
-2% -$1.77K ﹤0.01% 4081
2025
Q2 		$88.5K Buy
103,337
+3,164
+3% +$3.07K ﹤0.01% 4094
2025
Q1 		$92.9K Buy
100,173
+6,755
+7% +$7.43K ﹤0.01% 4050
2024
Q4 		$106K Buy
93,418
+16,862
+22% +$17K ﹤0.01% 4084
2024
Q3 		$88.8K Buy
76,556
+18,342
+32% +$23.6K ﹤0.01% 4138
2024
Q2 		$61.1K Hold
58,214
– – ﹤0.01% 4240
2024
Q1 		$70.4K Buy
58,214
+1,999
+4% +$2.24K ﹤0.01% 4253
2023
Q4 		$63K Buy
+56,215
New +$85K ﹤0.01% 4298

Other funds holding ESLA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Geode Capital Management's ESLA Position: Q3 2026 in Review

Geode Capital Management reduced its Estrella Immunopharma (ESLA) stake by 0.13% in Q3 2026, selling an estimated $131 and leaving 141,138 shares worth $65.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4149.

Geode Capital Management first reported a position in ESLA in Q4 2023 and has held it in 12 quarters since. The position peaked at $171K in Q4 2025. 11 funds tracked by Wall St. Rank hold ESLA as of Q3 2026.

  • Geode Capital Management held 141,138 shares of Estrella Immunopharma worth $65.9K as of Q3 2026.
  • Geode Capital Management sold 183 Estrella Immunopharma shares in Q3 2026, an estimated $131.
  • Estrella Immunopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #4149 holding.
  • Geode Capital Management first reported a position in Estrella Immunopharma in Q4 2023 and has held it in 12 quarters since.
  • Geode Capital Management's Estrella Immunopharma position peaked at $171K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.